24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund as an option for adults with relapsed or refractory mantle cell lymphoma who have previously had a Bruton's tyrosine kinase inhibitor. 

It is only recommended if the conditions in the managed access agreement for autologous anti‑CD19‑transduced CD3+ cells treatment are followed.

Read NICE technology appraisal guidance for brexucabtagene autoleucel